Integrin-Targeting Polypeptide Complexes for Tumor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting integrin proteins for tumor treatment are limited in efficacy and specificity, particularly for integrins such as αvβ5, α5β1, and αvβ3, which are associated with tumor growth, metastasis, and angiogenesis.
Innovation Solution
A polypeptide-like compound, composed of PD and ZT, or PD, ZT, and a linker, forms coordination complexes that inhibit integrin proteins like αvβ5, α5β1, and αvβ3, through amide, sulfonamide, or urea bonds, targeting these integrins to inhibit tumor growth and proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blocking antibodies or peptides are used to target integrins, then tumor growth and metastasis can be inhibited, but the therapeutic efficacy and specificity remain limited
Solution Approach 1:
The patent modifies the chemical structure of integrin-targeting compounds by changing parameters such as the core scaffold (from cyclic peptide to bicyclic structure), bond types (amide, sulfonamide, or urea bonds), and substituent groups. These parameter changes enable the compounds to maintain high affinity for integrins while improving therapeutic efficacy and specificity compared to existing blocking antibodies or peptides.
Solution Approach 2:
The invention creates composite molecular structures by combining a bicyclic core scaffold with specific amino acid residues (such as arginine, glycine, aspartate) and various substituent groups. This composite approach allows the compound to simultaneously achieve high binding affinity for integrin proteins and improved pharmacological properties, resolving the contradiction between efficacy and specificity.
2Reliability
If integrin-targeting compounds are developed to inhibit tumor growth, then therapeutic potential is improved, but the complexity of the compound structure increases
Solution Approach 1:
The integrin-targeting compound is segmented into distinct functional modules: a bicyclic core scaffold providing structural stability, specific amino acid residues (Arg-Gly-Asp sequence) for integrin binding, and substituent groups for modulating pharmacological properties. This segmentation allows for rational design and optimization while maintaining manageable structural complexity.
Solution Approach 2:
The patent systematically varies parameters such as the type of bonds (amide, sulfonamide, urea), the identity of amino acid residues, and the nature of substituent groups to optimize therapeutic potential. These controlled parameter changes enable improvement in efficacy without proportionally increasing structural complexity, as the core bicyclic scaffold remains consistent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide-like compound effectively targets and inhibits integrin proteins, providing a potential therapeutic approach for tumor treatment by inhibiting tumor growth and proliferation, and can be used in diagnosis or treatment of tumors.
Implementation Method 1
A polypeptide-like compound, composed of PD and ZT, or PD, ZT, and a linker, forms coordination complexes that inhibit integrin proteins
Data Source
AI summary
Provided are a polypeptide compound, and a complex and use thereof, specifically relating to the technical field of pharmaceutical chemistry. The polypeptide compound is shown as formula I. Compared with the prior art, the provided peptoid compound can target integrin proteins such as αvβ5, α5β1, and αvβ3, is enriched in tumor cells having high integrin expression, and has an important function in diagnosis and/or treatment of tumors.